Royal Bank of Canada analysts recently downgraded (NASDAQ: SRPT) Sarepta Therapeutics’ target price from an earlier $143.00 to a revised $132.00, as per their report on the company issued this Tuesday, March 2.
The commercial biopharmaceutical company was also marked with a revised “Outperform” rating by the brokerage. The new PT (price target) issued by Royal Bank of Canada suggests a 51.67% upside since the company’s previous close.
SRPT stocks traded at $87.03 this Tuesday. The company’s current market capitalization stands at $6.87 billion. It has a negative PE ratio of 11.13 along with a beta of 2.1 at the moment. The current ratio is 6.14, the quick ratio at 5.56, and the debt-to-equity ratio at 0.79. The 12-monthly high to low ranges from $181.83 to $77.01. The 50SMA (Simple Moving Average) stands at $90.86 and its 1320SMA stands at $132.11.
SRPT (NASDAQ) Technical Stock Analysis
The quarterly earnings report for the previous fiscal quarter was released by the company on the 1st of March. The earnings stood at $1.84 EPS for that quarter as opposed to the general consensus on the estimated earnings of $1.99 proposed by analysts at Zacks Investment Research. The company’s return on equity currently stands at -61.62% along with a net margin of -121.30%.
The estimated income for the firm was marked at $145.54 million but it made $145.10 million for the quarter. Available data show that the company’s revenue increased by 45.0% on a y-o-y basis. During the corresponding quarter previous year, the company posted an EPS of 3.16. Analysts expect the company to post Full Year 2020 earnings per share of -8.2.
NASDAQ: SRPT has recently been the subject of a lot of reports by equities analysts. Some such as SVB Leerink, Piper Sandler, Robert W. Baird, Mizuho, and so on have posted reports on this firm over the last few months.
The recent consensus rating of Sarepta Therapeutics stands at “Hold” and the consensus on the target price is $149.27. Several hedge funds have also altered their shareholdings in the company recently.
